TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
Ximelagatran
antithrombotics
systematic review
meta-analysis
network meta-analysis
H 376-95 - H 376 95 - Exanta - xi-melagatran - ximelagatran
Select
acute coronary syndrome
atrial fibrillation
thrombosis prevention
venous thrombosis
direct anti-Xa
oral direct thrombin inhibitor
oral factor Xa inhibitor
vs discontinuation
vs placebo
vs placebo or control
vs anticoagulant
vs Low molecular weight heparin
pdf
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
Major bleeding (14)
All cause death (8)
Fatal bleeding (8)
Venous thromboembolism (6)
Acute coronary syndrome (6)
Cardiovascular death (4)
ischemic stroke (4)
major or clinically relevant non-major bleeding (4)
fatal pulmonary embolism (4)
non-fatal pulmonary embolism (4)
any bleedings (4)
Non fatal stroke (3)
hypertransaminasemia (3)
TE event or ischemic stroke or systemic embolism (3)
Lifethreatening major bleeding (3)
Non-lifethreatening major bleeding (3)
Gastrointestinal major bleeding (3)
Coronary event (3)
stroke (fatal and non fatal) (3)
systemic thrombo-embolic complication (3)
Haemmorhagic stroke (3)
Fatal stroke (3)
recurrent DVT (3)
VTE (3)
thrombo-embolic event (cerebral or systemic) (3)
Bleeding (1)
death at 3 months (1)
Long term death (1)
recurrent VTE (1)
Recurrent thromboembolic event (1)
Recurrent DVT/DVT extension (symptomatic) (1)
Thrombocytopenia (1)
cardiovascular events (1)
stent thrombosis (1)
cardiac event (fatal and non fatal ) (1)
myocardial infarction (fatal and non fatal) (1)
major or minor bleeding (1)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
Major bleeding
All cause death
acute coronary syndrome
ESTEEM, 2003
ximelagatran
placebo
Exploratory
-
atrial fibrillation
SPORTIF II (ximelagatran vs warfarin standard dose), 2002
ximelagatran
warfarin standard dose
Risk of bias
-
SPORTIF III, 2003
ximelagatran
warfarin standard dose
Risk of bias
suggesting
-29%
-1%
SPORTIF V, 2005
ximelagatran
warfarin standard dose
Low risk of bias
suggesting
-25%
-6%
thrombosis prevention
METHRO I, 2002
ximelagatran
Dalteparin
negative
METHRO II, 2002
ximelagatran
Dalteparin
Low risk of bias
suggesting
101%
Phase II (Heit), 2001
ximelagatran
Enoxaparin
Low risk of bias
negative
-100%
Platinum (Colwell), 2003
ximelagatran
Enoxaparin
Low risk of bias
negative
-12%
METHRO III, 2002
ximelagatran
Enoxaparin
Low risk of bias
negative
-14%
EXPRESS, 2003
ximelagatran
Enoxaparin
Low risk of bias
suggesting
189%
venous thrombosis
THRIVE III, 2003
ximelagatran
discontinuation
Low risk of bias
suggesting
20%
-14%
Schulman (subgroup), 2003
ximelagatran
placebo
patients with cancer
-
Fiessinger , 2005
ximelagatran
LMWH/VKA
Low risk of bias
-
THRIVE I, 2003
ximelagatran (without LMWH)
LMWH/VKA
-
×
Modal title
